Q-omics provides the consensus-scored BEND7 profile across patient tissues and cancer cell-line models. BEND7 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in READ. Among the 18 cancer types available for tumor–normal comparison, BEND7 is differentially expressed in 9, with the highest sampling consensus in KICH. Additionally, BEND7 RNA expression shows 19,054 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight READ, KICH, and UVM as cancer lineages where BEND7 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for BEND7 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes BEND7 survival associations across molecular data types. BEND7 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (3) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible BEND7 RNA expression–survival associations across cancer types. High BEND7 expression shows unfavorable associations in HNSC and UCEC, but favorable associations in READ, KIRC, LGG and ACC. The READ Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify READ as the clearest survival context for BEND7 RNA expression.
This table summarizes BEND7 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 3. The strongest signals are observed in KICH for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for BEND7. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. BEND7 shows lower tumor expression in KICH, BRCA, LUSC, UCEC and LUAD and higher tumor expression in LIHC. The KICH box plot shows higher BEND7 RNA expression in normal versus tumor tissue (log2 FC = −1.047, t-test p < 0.001).
This table shows molecular features associated with BEND7 in patient tissues and cancer cell lines. In patient samples, BEND7 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, BEND7 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and LUNG_NSCLC_LUAD.
